Research community previously filed under “Radiology, Nuclear Medicine and Imaging”

PET and SPECT Imaging and Targeted Radionuclide Therapy for Prostate and Neuroendocrine Cancers

Mostly in the field Nuclear Medicine, Radiopharmaceuticals and Solid Tumor Oncology (66% of its papers), one of 3 communities there

Papers 83,028
Elements 10
Keywords & sectors 124
Leading venue European Journal of Nuclear Medicine and Molecular Imaging

PET and SPECT Imaging and Targeted Radionuclide Therapy for Prostate and Neuroendocrine Cancers

This community focuses on the development and clinical application of positron emission tomography (PET) and single-photon emission computed tomography (SPECT) for cancer diagnosis, alongside targeted radionuclide therapies that deliver radiation directly to tumor cells. The work primarily addresses metastatic prostate cancer and neuroendocrine tumors, utilizing specific radiotracers to visualize disease and treat resistant cases.

The research centers on the use of fluorine-18 and technetium-99m for diagnostic imaging, with a heavy emphasis on prostate-specific membrane antigen (PSMA) and somatostatin receptor targeting. Key applications include 18F-FDG PET for metabolic assessment, PSMA PET for prostate cancer staging, and peptide receptor radionuclide therapy (PRRT) using lutetium-177 for neuroendocrine tumors. The community also investigates the integration of PET with magnetic resonance imaging (MRI) and computed tomography (CT) to improve diagnostic accuracy. Clinical trials and case reports dominate the literature, focusing on patient outcomes, treatment response evaluation, and the management of metastatic disease in prostate, breast, and lung cancers.

The largest share of the community's output is found in technetium research, accounting for 27.3% of all technetium research, and 5,754 papers here. Lutetium research also shows a high concentration, representing 25.9% of all lutetium research, with 1,769 papers in this group.

The community comprises 83,028 papers, published predominantly in the European Journal of Nuclear Medicine and Molecular Imaging, Clinical Nuclear Medicine, and the Journal of Nuclear Medicine.

Recent work includes phase 3 trials for lutetium-177 PSMA-617 in metastatic prostate cancer and reviews on the molecular blueprint of targeted radionuclide therapy. The newest papers also feature studies on biparametric MRI for prostate cancer diagnosis and trial designs for patients with metastatic castration-sensitive prostate cancer.

Recurring themes in the literature

Phrases that recur across this community's paper titles -- a quick map of its sub-topics, drawn straight from the titles themselves.

  • prostate cancer 2434
  • pet imaging 803
  • castration-resistant prostate 587
  • breast cancer 524
  • case report 511
  • positron emission 491
  • metastatic castration-resistant 484
  • emission tomography 472
  • nuclear medicine 455
  • radionuclide therapy 371
  • radioligand therapy 363
  • molecular imaging 333
  • computed tomography 308
  • neuroendocrine tumors 295
  • lymph node 292
  • 18f-fdg pet 284
  • cancer patients 281
  • magnetic resonance 272
  • fdg pet 267
  • membrane antigen 246
  • sentinel lymph 233
  • resonance imaging 213
  • prostate-specific membrane 212
  • patients metastatic 201

Papers behind this description

Most cited
The Lancet · 2024 · 826 citations
European Urology · 2023 · 862 citations
Nature Reviews Drug Discovery · 2022 · 1141 citations
European Journal of Endocrinology · 2023 · 766 citations
Journal of the National Comprehensive Cancer Network · 2023 · 604 citations
Newest
JAMA · 2025 · 63 citations
Journal of Clinical Oncology · 2026 · 45 citations
Nature Medicine · 2025 · 52 citations
Nature Reviews Clinical Oncology · 2025 · 38 citations
Annals of Oncology · 2025 · 37 citations

A sample from the 16 papers behind this description. Create a free account to see them all.